Literature DB >> 2751327

Opsonic activity in serum from septic infants treated with intravenous immunoglobulin.

L Maródi1, A Kalmár, I Szabó.   

Abstract

Thirteen infants with staphylococcal sepsis and reduced opsonic activity received infusions of acid treated immunoglobulin together with antibiotics. Opsonic activity (using Staphylococcus aureus (type 42D) as the test organism), haemolytic activity of complement, and concentrations of complement C3 and IgG were measured in serum prepared before and after three days of treatment with immunoglobulin at a dose of 250-300 mg/kg/day. There was increased ingestion of S aureus by normal human granulocytes in the presence of fresh serum prepared after infusion of immunoglobulin and significantly increased opsonic activity of heat inactivated serum after treatment with immunoglobulin. The haemolytic activity of complement and concentrations of complement C3 were not influenced, and serum concentrations of IgG increased as the result of receiving a total of 800-900 mg/kg immunoglobulin over a period of three days. This study shows that administration of acid treated IgG to septic infants leads to functionally increased opsonisation.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2751327      PMCID: PMC1791970          DOI: 10.1136/adc.64.4.530

Source DB:  PubMed          Journal:  Arch Dis Child        ISSN: 0003-9888            Impact factor:   3.791


  12 in total

1.  Quantitation of the third component of human complement attached to the surface of opsonized bacteria: opsonin-deficient sera and phagocytosis-resistant strains.

Authors:  H A Verbrugh; W C van Dijk; M E van Erne; R Peters; P K Peterson; J Verhoef
Journal:  Infect Immun       Date:  1979-12       Impact factor: 3.441

Review 2.  Molecular biology and chemistry of the alternative pathway of complement.

Authors:  H J Müller-Eberhard; R D Schreiber
Journal:  Adv Immunol       Date:  1980       Impact factor: 3.543

3.  Opsonic activity of cord blood sera against various species of microorganism.

Authors:  L Máródi; P C Leijh; A Braat; M R Daha; R van Furth
Journal:  Pediatr Res       Date:  1985-05       Impact factor: 3.756

4.  Immune globulin for intravenous use: enhancement of in vitro opsonophagocytic activity of neonatal serum.

Authors:  L B Givner; M S Edwards; D C Anderson; C J Baker
Journal:  J Infect Dis       Date:  1985-02       Impact factor: 5.226

5.  A micromethod for the separate evaluation of phagocytosis and intracellular killing of Staphylococcus aureus by human monocytes and granulocytes.

Authors:  L Maródi; P C Leijh; R Van Furth
Journal:  J Immunol Methods       Date:  1983-02-25       Impact factor: 2.303

6.  Treatment of acute idiopathic thrombocytopenia of childhood with intravenous infusions of gammaglobulin.

Authors:  J B Bussel; A Goldman; P Imbach; I Schulman; M W Hilgartner
Journal:  J Pediatr       Date:  1985-06       Impact factor: 4.406

7.  High-dose intravenous gammaglobulin for idiopathic thrombocytopenic purpura in childhood.

Authors:  P Imbach; S Barandun; V d'Apuzzo; C Baumgartner; A Hirt; A Morell; E Rossi; M Schöni; M Vest; H P Wagner
Journal:  Lancet       Date:  1981-06-06       Impact factor: 79.321

8.  Staphylococcus aureus: biology, mechanisms of virulence, epidemiology.

Authors:  M L Cohen
Journal:  J Pediatr       Date:  1986-05       Impact factor: 4.406

9.  Selective immunodeficiency affecting staphylococcal response.

Authors:  M Monteil; J Hobbs; K Citron
Journal:  Lancet       Date:  1987-10-17       Impact factor: 79.321

10.  The enhancement of bacterial phagocytosis by serum. The role of complement components and two cofactors.

Authors:  R B Johnston; M R Klemperer; C A Alper; F S Rosen
Journal:  J Exp Med       Date:  1969-06-01       Impact factor: 14.307

View more
  1 in total

1.  Staphylococcal superantigen-like protein 3 binds to the Toll-like receptor 2 extracellular domain and inhibits cytokine production induced by Staphylococcus aureus, cell wall component, or lipopeptides in murine macrophages.

Authors:  Ryosuke Yokoyama; Saotomo Itoh; Go Kamoshida; Takemasa Takii; Satoshi Fujii; Tsutomu Tsuji; Kikuo Onozaki
Journal:  Infect Immun       Date:  2012-06-04       Impact factor: 3.441

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.